Covid News: C D C Loosens Mask Guidance for Most Outdoor Activities at Summer Camps nytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nytimes.com Daily Mail and Mail on Sunday newspapers.
Written by Steven HansenThe U.S. new cases 7-day rolling average are 19.2 % LOWER than the 7-day rolling average one week ago and U.S. deaths due to coronavirus are now 17.7 % HIGHER than the rolling average one week ago. Today s posts include:
CureVac
CureVac s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation
DGAP-News: CureVac / Key word(s): Study
CureVac s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation
28.05.2021 / 22:30
CureVac s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward
Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation
-
COVID-19 cases
TÜBINGEN, Germany/ BOSTON, USA - May 28, 2021 -
CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ( mRNA ), today announced that the independent Data Safety Monitoring Board (DSMB) has confirmed that the pivotal Phase 2b/3 study (HERALD) for CureVac s first-generation COVID-19 vaccine candi
TEL AVIV, Israel and RALEIGH, N.C., May 27, 2021 /PRNewswire/ RedHill Biopharma Ltd. (Nasdaq: RDHL) ( RedHill or the Company ), a specialty biopharmaceutical company, today reported its financial results and operational highlights for the first quarter ended March 31, 2021.
Dror Ben-Asher, RedHill s Chief Executive Officer, said: The progress of our two novel, oral COVID-19 programs has put RedHill at the forefront of oral COVID-19 therapeutics development. Opaganib, one of the most advanced and promising novel, dual-mode of action, oral drug candidates in development for COVID-19, now has almost 100% enrollment in its global 464-patient Phase 2/3 study in severe COVID-19.
Mr. Ben-Asher continued: Commercially, a strong end to the first quarter has set up 2021 for growth, reversing a slow start to the year across the industry. Movantik s new prescriptions in the first quarter outperformed the same quarter last year, while Talicia s growth in prescription volume, repeat pres